SIGN UP or LOGIN
YOUR CART
SUPPORT

Important Notice: Due to the Passover holiday our shipping department in Israel will be closed April 15-23.
Thank you for your patience and understanding.

  • US Name:

    Coralan, Servier

  • Israeli Names:

    Coralan

  • Active Ingredients:

    Ivabradine

  • Brand Manufacturer:

    Servier Laboratories

  • Manufacturer Location:

    Ireland

Coralan, Servier

Ivabradine is a novel treatment for stable angina pectoris.

BrandCoralan 7.5mg56 Tablets 18982Servier Laboratories 1305
-
+
$110.00
spinner
BrandCoralan5mg 56 Tablets18981 Servier Laboratories1304
-
+
$46.66
spinner

Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers.

Luminous phenomena (phosphenes) were reported by 14.5% of patients, described as a transient enhanced brightness in a limited area of the visual field. They are usually triggered by sudden variations in light intensity. The onset of phosphenes is generally within the first two months of treatment after which they may occur repeatedly. Phosphenes were generally reported to be of mild to moderate intensity. All phosphenes resolved during or after treatment, of which a majority (77.5%) resolved during treatment. Fewer than 1% of patients changed their daily routine or discontinued the treatment in relation with phosphenes. Bradycardia was reported by 3.3% of patients particularly within the first 2 to 3 months of treatment initiation. 0.5% of patients experienced a severe bradycardia below or equal to 40 bpm.

Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contraindication or intolerance for beta-blockers. For the different doses, film-coated tablets containing 5 mg and 7.5 mg ivabradine are available. The usual recommended starting dose of ivabradine is 5 mg twice daily. After three to four weeks of treatment, the dose may be increased to 7.5 mg twice daily depending on the therapeutic response. If, during treatment, heart rate decreases persistently below 50 beats per minute (bpm) at rest or the patient experiences symptoms related to bradycardia such as dizziness, fatigue or hypotension, the dose must be titrated downward including the possible dose of 2.5 mg twice daily (one half 5 mg tablet twice daily). Treatment must be discontinued if heart rate below 50 bpm or symptoms of bradycardia persist.

Required

Send Your Prescription

Secure Payment

No Hidden Fees

Fast Shipping

Typically Under 7 days

Israel

Israel Turns 74 Years Old

In the first week of May, we will be observing two of the most important days in the calendar of the State of Israel. This year on May 4th, the whole country marks the  Israel

Read More »
drugs

Venezuela’s Medicine Blockage

Venezuela is experiencing  a severe humanitarian crisis with shortages in food and medical care. Norma Camero Reno is a Venezuelan born lawyer and founder of the non-profit organization, Move Foundation, which has been sending much needed

Read More »